FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
Cellectis(CLLS) Newsfilter·2024-07-25 20:30NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug (ODD) and Rare Pediatric Disease Designation (RPDD) Status to UCART22 product candidate for the treatment of Acute Lymphoblastic Leukemia (ALL). Mark Frattini, M.D., Ph.D., Chief Med ...